BioArctic and Eisai sign research evaluation agreement regarding BAN2802
Stockholm, Sweden, April 20, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai…
16,140€
0,62%
Echtzeit-Aktienkurs BioArctic AB
Bid:
Ask:
Nachrichten zur BioArctic AB Aktie
Notice of Annual General Meeting in BioArctic AB (publ)
The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held…
AAX Biotechs Technology to be Utilized in BioArctic’s Research Project
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is excited to announce that BioArctic AB, a…
The Nomination Committees proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Stockholm April 16, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic…
BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
Stockholm, Sweden, April 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) commitment to its Sustainable Innovation approach –…
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed
Stockholm, Sweden, April 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has…
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
Stockholm, Sweden March 22, 2024 – BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral…
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease
Stockholm, Sweden, March 19, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctics founder, Professor Lars…
BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
Stockholm, Sweden, March 7, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a presentation including…
Number of shares and votes in BioArctic AB (publ) as of February 29, 2024
Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during February issued…
Latest data on lecanemab to be presented at the 2024 AD/PD™ congress
Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and its partner…